Eyepoint Pharmaceuticals Inc EYPT

$17.08 -0.74 (-4.15%)

Valuation

Market cap
1,468,641,000
Revenue TTM
$43,270,000
Net income TTM
$-130,870,000
PE ratio
0.00
Forward PE
—
Profit margin
-302.45%
Debt to equity
0.00

Trading

Volume
1,429,818
Avg volume
1,347,702
Day's range
$17.05 – $18.17
Shares out
82,787,000
Stochastic %K
98%
Beta
1.67
Analysts
Strong Sell
Price target
$34.00

Price

Company profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining...

Show more

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 926 5000
Website
https://eyepoint.bio
Address
480 Pleasant Street, Suite C-400, Watertown, United States

Latest news

No headlines yet.

Stocktwits

Jdliberty Oct 2, 11:09 PM
$EYPT that would make them a delicious takeover target?
1 replies
BLtheKid Oct 2, 5:22 PM
$EYPT the real kicker on this would be if they meet the endpoint with LUCIA and it barely gets baked into the stock price, moving only to 4.50 or something like that
3 replies
MaGo1981 Oct 2, 2:09 PM
$EYPT Watching EYPT drift lower is frustrating, but for those who truly believe in LUCIA, it doesn’t change much. LUCIA remains a binary-risk event, and the outcome will ultimately matter far more than the short-term price action. I don’t have the financial room to add, so I’m just waiting to see how LUCIA plays out. If LUCIA fails, the money invested was at risk anyway. If it succeeds, there’s still plenty of upside. For long-term believers, the current weakness could actually be an opportunity to add at much lower prices.
3 replies
newmoneyking Oct 2, 1:59 PM
$EYPT infinity money graveyard.
0 replies
BrexitIsStupid Oct 1, 8:04 PM
$EYPT I bought some January 27 CALLS but everything depend on LUCIA
1 replies
rizzato Oct 1, 7:54 PM 0 replies
Morpheus87 Oct 1, 7:28 PM
$EYPT what a POS
0 replies
rizzato Oct 1, 7:15 PM
$EYPT unfortunately we do not have an updated situation about the big institution shareholders but it seems they are more adding than selling
0 replies